News & Updates

Show Multimedia Only

Investigational triple–hormone-receptor agonist reduces fat mass in people with T2D

10 Jul 2025

Treatment with retatrutide—an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors—appears to result in greater total body fat mass reduction in individuals with type 2 diabetes (T2D) and high BMI when compared with placebo and dulaglutide, according to a substudy of a phase II trial.

Investigational triple–hormone-receptor agonist reduces fat mass in people with T2D

10 Jul 2025

Pembrolizumab + CCRT ups survival in high-risk LACC

10 Jul 2025 by

Treatment with the combination of pembrolizumab and concurrent chemoradiotherapy (CCRT), followed by pembrolizumab maintenance, led to a sustained, long-term survival benefit in patients with high-risk, locally advanced cervical cancer (LACC) compared with CCRT alone, according to the final analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial presented at ASCO 2025.

Pembrolizumab + CCRT ups survival in high-risk LACC

10 Jul 2025

SGLT-2 inhibitors may provide liver-related benefits to patients with cirrhosis

09 Jul 2025 by

The use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitor helps lower the incidence of serious liver events among patients with cirrhosis who are receiving diuretic therapy, according to a study.

SGLT-2 inhibitors may provide liver-related benefits to patients with cirrhosis

09 Jul 2025

Oral mitapivat beneficial in the treatment of non-transfusion-dependent thalassaemia

09 Jul 2025

Mitapivat, an oral activator of pyruvate kinase, appears to increase haemoglobin concentration and improve fatigue in adults with non-transfusion-dependent (NTD) α-thalassaemia or NTD β-thalassaemia, according to the double-blind phase III ENERGIZE study.

Oral mitapivat beneficial in the treatment of non-transfusion-dependent thalassaemia

09 Jul 2025

Pramipexole augmentation helps in treatment-resistant depression, but side effects noted

08 Jul 2025 by

Augmenting antidepressants with pramipexole substantially improves treatment-resistant depression, although it comes with some adverse effects, according to the results of a randomized controlled trial.

Pramipexole augmentation helps in treatment-resistant depression, but side effects noted

08 Jul 2025

SSRI use, depression predict worse sexual outcomes

08 Jul 2025 by

Depression and the use of SSRIs appear to significantly contribute to an individual’s sexual functioning, distress, and pleasure, according to a study.

SSRI use, depression predict worse sexual outcomes

08 Jul 2025

Linperlisib plus chidamide shows therapeutic potential in cutaneous T-cell lymphoma

08 Jul 2025

Combination treatment with the PI3Kδ inhibitor linperlisib plus the histone deacetylase inhibitor chidamide has demonstrated promising clinical activity in relapsed or refractory cutaneous T-cell lymphoma (CTCL) in a phase I study.

Linperlisib plus chidamide shows therapeutic potential in cutaneous T-cell lymphoma

08 Jul 2025

Delgocitinib cream safe, effective for long-term use in eczema

07 Jul 2025 by

Long-term treatment with delgocitinib is well-tolerated and raises no major safety concerns among patients with chronic hand eczema (CHE), results of the DELTA 3 trial have shown. Its use also maintains disease control for up to 52 weeks.

Delgocitinib cream safe, effective for long-term use in eczema

07 Jul 2025

Aspirin use may prevent CRC metastasis

07 Jul 2025

The use of aspirin appears to provide protective benefits against metastasis in patients with colorectal cancer (CRC), reports a study.

Aspirin use may prevent CRC metastasis

07 Jul 2025

Topical BRAF inhibitor relieves EGFR-induced acneiform eruption

07 Jul 2025 by

LUT014 gel, a novel, small-molecule, topical formulation of a BRAF inhibitor, relieves acneiform rash toxicities from anti-EGFR therapies, findings from a phase II study suggest.

Topical BRAF inhibitor relieves EGFR-induced acneiform eruption

07 Jul 2025

News & Updates

Filter by Specialty:

Specialty:

Investigational triple–hormone-receptor agonist reduces fat mass in people with T2D

Investigational triple–hormone-receptor agonist reduces fat mass in people with T2D

Pembrolizumab + CCRT ups survival in high-risk LACC

Pembrolizumab + CCRT ups survival in high-risk LACC

SGLT-2 inhibitors may provide liver-related benefits to patients with cirrhosis

SGLT-2 inhibitors may provide liver-related benefits to patients with cirrhosis

Oral mitapivat beneficial in the treatment of non-transfusion-dependent thalassaemia

Oral mitapivat beneficial in the treatment of non-transfusion-dependent thalassaemia

Pramipexole augmentation helps in treatment-resistant depression, but side effects noted

Pramipexole augmentation helps in treatment-resistant depression, but side effects noted

SSRI use, depression predict worse sexual outcomes

SSRI use, depression predict worse sexual outcomes

Linperlisib plus chidamide shows therapeutic potential in cutaneous T-cell lymphoma

Linperlisib plus chidamide shows therapeutic potential in cutaneous T-cell lymphoma

Delgocitinib cream safe, effective for long-term use in eczema

Delgocitinib cream safe, effective for long-term use in eczema

Aspirin use may prevent CRC metastasis

Aspirin use may prevent CRC metastasis

Topical BRAF inhibitor relieves EGFR-induced acneiform eruption

Topical BRAF inhibitor relieves EGFR-induced acneiform eruption